Article
Identification of a minimal biomarker profile in head-and-neck squamous cell carcinoma tumors
2021-11-17
Abstract excerpt
Although important advances have been made in the knowledge of the molecular mechanisms leading to the development, of head and neck squamous cell carcinoma (HNSCC), only PDL1 is used for the immunotherapy (pemborlizumab) treatment in the first line of metastatic or recurrent disease. There are no other molecular biomarkers currently used in clinical practice. The objective of the study was to identify transcripti...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d22de480-7405-555d-8ffd-f0cf58e07e05
- DOI
- 10.1101/2021.11.12.468359
